Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

CME Group Inc (CME): Will Futures Keep Gaining Popularity?

NASDAQ OMX Group, Inc. (NASDAQ:NDAQ) provides trading, exchange technology, and securities listing services.  The stock trades at just 14 times earnings, which may seem like a bargain at first, however I’m not so sure. NASDAQ’s earnings and revenues are relatively unpredictable.  Trading volumes can fluctuate wildly, and in the most recent quarter, volumes were down a full 20% from the quarter before.

Dividends

CME Group has paid a dividend every year since 2003 and has increased it regularly, from 13 cents per share in 2003 to $1.80 currently, or a yield of 3.12%.  I would be very surprised if there wasn’t another increase this year.  Something in the $2.00 per share range is what I would expect.

Conclusion

I believe CME is a fairly valued company in arguably the fastest growing segment of the financial services industry (futures and options).  More important than the earnings numbers themselves will be the company’s outlook for the future, i.e., is the growth in futures trading volumes going to continue?

The article CME Group: Will Futures Keep Gaining Popularity? originally appeared on Fool.com and is written by Matthew Frankel.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Biotech Insider Alert - $5 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!